Stable formulations of programmed death receptor 1 (PD-1) antibodies and methods of use thereof
US11633476B2 · kind B2 · utility
2Cited by
55References
21Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 1, 2018 |
| Grant date | Apr 25, 2023 |
| Priority date | — |
| Expiry date | Oct 14, 2039 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/24
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention relates to stable formulations of antibodies against human programmed death receptor PD-1, or antigen binding fragments thereof. In some embodiments the formulations of the invention comprise between 5-200 mg/mL anti-PD-1 antibody, or antigen binding fragment thereof. The invention further provides methods for treating various cancers with stable formulations of the invention. In some embodiments of the methods of the invention, the formulations are administered to a subject by intravenous or subcutaneous administration.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.